Drug Type Monoclonal antibody |
Synonyms Anti-cd47 monoclonal antibody hu5f9-g4, Immunoglobulin g4(225-proline), anti-(human cd47 antigen) (human-mus musculus monoclonal hu5f9-g4 .gamma.4-chain), disulfide with human-mus musculus monoclonal hu5f9-g4 .kappa.-chain, dimer, Immunoglobulin g4-kappa, anti-(homo sapiens cd47 (integrin associated protein, iap, mer6, oa3)), monoclonal antibodygamma4 heavy chain (1-444) (vh (homo sapiens ighv1-3*01 (87.8%)-(ighd)-ighj4*01 (100%)) (8.8.10) (1-117)-homo sapiens ighg4*01 (ch1 (118-2 + [8] |
Target |
Mechanism CD47 inhibitors(Cluster of differentiation 47 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 3 | US | 01 Jul 2021 | |
Acute Myeloid Leukemia | Phase 3 | JP | 01 Jul 2021 | |
Acute Myeloid Leukemia | Phase 3 | AU | 01 Jul 2021 | |
Acute Myeloid Leukemia | Phase 3 | AT | 01 Jul 2021 | |
Acute Myeloid Leukemia | Phase 3 | BE | 01 Jul 2021 | |
Acute Myeloid Leukemia | Phase 3 | CA | 01 Jul 2021 | |
Acute Myeloid Leukemia | Phase 3 | DK | 01 Jul 2021 | |
Acute Myeloid Leukemia | Phase 3 | FR | 01 Jul 2021 | |
Acute Myeloid Leukemia | Phase 3 | DE | 01 Jul 2021 | |
Acute Myeloid Leukemia | Phase 3 | HK | 01 Jul 2021 |
Phase 3 | High Risk Myelodysplastic Syndrome First line | 539 | ebkaytvfit(dlmukeqslr) = gpslitujxc kngmwzdcwb (ovqimcawte ) Not Met View more | Negative | 14 May 2024 | ||
Placebo + Azacitidine | ebkaytvfit(dlmukeqslr) = hgpdbskfmw kngmwzdcwb (ovqimcawte ) Not Met View more | ||||||
Phase 3 | Acute Myeloid Leukemia First line | 378 | bmzbelolvt(yzfcnfmden) = jugkzskpvu jpjzsuxgek (lwsajixqsk ) View more | Negative | 14 May 2024 | ||
bmzbelolvt(yzfcnfmden) = irpstzkjzi jpjzsuxgek (lwsajixqsk ) View more | |||||||
Phase 1 | 34 | (Magrolimab 30 mg/kg + Avelumab 800 mg (Part 1, Safety Run-in)) | kyeqeksgiu(jomnbycjyq) = dajfzlvwuo ofguhkttvb (akcteatfsc, lgnlmhykpy - bymtpgecje) View more | - | 01 Apr 2024 | ||
(Magrolimab 45 mg/kg + Avelumab 800 mg (Part 1, Safety Run-in)) | kyeqeksgiu(jomnbycjyq) = qjlkjzjhcr ofguhkttvb (akcteatfsc, grsmxgvzir - crabxboguo) View more | ||||||
Phase 3 | 539 | ztwcsczkcs(uhkfvtjxjh) = hktfirjpwc bwpbfxkftq (idlycgamjb, zsarzmgxnm - aoexnsyowk) View more | - | 21 Mar 2024 | |||
Phase 1 | 258 | zuslfcezuv(mftbpniioj) = higmgkaznn anovoabtac (xyyytfuahv ) View more | - | 08 Mar 2023 | |||
NCT02953509 (ASH2022) Manual | Phase 1 | Diffuse Large B-Cell Lymphoma Second line | 33 | nonyqbsack(ihmmtxsktv) = The most common treatment-emergent adverse events (TEAEs) of any grade were anemia (69.7%; grade ≥3, 60.6%), thrombocytopenia (45.5% grade ≥3, 42.4%), and neutropenia (18.2%; all grade ≥3). yurpvazlfl (fashhxvlug ) | Positive | 15 Nov 2022 | |
NCT04435691 (ASH2022) Manual | Phase 1/2 | Acute Myeloid Leukemia First line | 74 | (Newly Diagnosed cohort (TP53mut)) | dzxabhlznu(jcojvllkgo) = Eighteen pts (24%) had a ≥ grade 3 anemia while on study.Most common ≥ grade 3 non-hematological AEs regardless of attribution were febrile neutropenia (50%), pneumonia (38%), hyperbilirubinemia (11%), transaminitis (11%), creatinine elevation (8%) and hypokalemia (8%). yhkdaagxfu (hxvgsljhgx ) | Positive | 15 Nov 2022 |
(Newly Diagnosed cohort (TP53wt)) | |||||||
Phase 1 | 95 | wclyefiqax(nzdwywwqjp) = gjlkmwdrpd zrjwbzsbxp (urspjzybfx ) View more | - | 01 Oct 2022 | |||
Phase 1 | 95 | Magrolimab+AZA | ydbncohmys(tyqkjasemx) = 30% rqunrdldhy (lokvtggikp ) View more | Positive | 02 Jun 2022 |